Triethylenetetramine
- Generic Name
- Triethylenetetramine
- Brand Names
- Cuvrior, Syprine, Cuprior, Cufence
- Drug Type
- Small Molecule
- Chemical Formula
- C6H18N4
- CAS Number
- 112-24-3
- Unique Ingredient Identifier
- SJ76Y07H5F
- Background
Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, spermidine and spermine. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease, TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and tolerant to penicillamine.
TETA has been investigated in clinical trials for the treatment of heart failure in patients with diabetes.
- Indication
Triethylenetetramine is a copper chelator indicated for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine.
- Associated Conditions
- Wilson's Disease
The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Manchester University NHS Foundation Trust
- Target Recruit Count
- 154
- Registration Number
- NCT04706429
- Locations
- 🇬🇧
University Hospitals of Leicester NHS Foundation Trust, Leicester, United Kingdom
🇬🇧Liverpool Heart and Chester Hospital NHS Foundation Trust, Liverpool, United Kingdom
🇬🇧Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom
Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Innolife Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT03875183
- Locations
- 🇺🇸
Stern Cardiovascular, Germantown, Tennessee, United States
🇺🇸UCLA School of Medicine, Torrance, California, United States
🇺🇸Innovative Research of West Florida, Inc., Clearwater, Florida, United States
Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease
- Conditions
- Wilson Disease
- Interventions
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Orphalan
- Target Recruit Count
- 77
- Registration Number
- NCT03539952
- Locations
- 🇧🇷
Nucleo de Pesquisa e Desenvolvimento de Medicamentos - Universidade Federal do Ceará - Rodolfo Teófilo, Fortaleza, Brazil
🇮🇹DiSCOG Gastroenterology Unit, Padova, Italy
🇫🇷Centre National de Référence Wilson, Hôpital Lariboisière, Paris, France
Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer
- Conditions
- Ovarian Neoplasms Malignant (Excl Germ Cell)Peritoneal CarcinomaFallopian Tube Cancer
- Interventions
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT03480750
A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients
- Conditions
- Trientine Treatment for Wilson's Disease
- First Posted Date
- 2017-10-03
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- Excelsior
- Target Recruit Count
- 48
- Registration Number
- NCT03299829
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan
Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine
- First Posted Date
- 2015-04-27
- Last Posted Date
- 2017-08-23
- Lead Sponsor
- Univar BV
- Target Recruit Count
- 90
- Registration Number
- NCT02426905
- Locations
- 🇩🇪
Universitätsklinik Heidelberg, Heidelberg, Germany
🇬🇧Kings College Hospital, London, United Kingdom
🇮🇹San Paolo Hospital UOC, Milan, Italy
A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Univar BV
- Target Recruit Count
- 20
- Registration Number
- NCT01874028
- Locations
- 🇩🇪
Universitätsklinik Heidelberg, Heidelberg, Germany
Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus
- Conditions
- Macular Edema Following Cataract Surgery
- Interventions
- Other: For Arm B there is no therapeutic intervention other than standard of care, which is cataract surgery.
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- University of British Columbia
- Registration Number
- NCT01295073
- Locations
- 🇨🇦
Univeristy of British Columbia/Vancouver Coastal Health Authority - Eye Care Center, Vancouver, British Columbia, Canada
Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy
- Conditions
- Diabetic Retinopathy
- Interventions
- Drug: Oral placebo capsules
- First Posted Date
- 2010-10-04
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 3
- Registration Number
- NCT01213888
- Locations
- 🇨🇦
Eye Care Centre - Vancouver Coastal Health, Vancouver, British Columbia, Canada
Trientine and Carboplatin in Advanced Malignancies
- Conditions
- Advanced Cancers
- Interventions
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT01178112
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.